the use of initial doses .30 mg/day. According to the SLR on prognostic factors and based on clinical experience, the group agreed upon the existence of various PMR subgroups that are characterized by different risks of relapse, prolonged GC therapy and/or GC-related adverse events as well as by various comorbidities and co-medications. As there are insufficient data to make evidence-based recommendations for all conceivable subgroups, and taking current clinical practice into account The group